Jared Weiss
YOU?
Author Swipe
View article: Using the galactose‐α‐1,3‐galactose enzyme‐linked immunosorbent assay to predict anaphylaxis in response to cetuximab
Using the galactose‐α‐1,3‐galactose enzyme‐linked immunosorbent assay to predict anaphylaxis in response to cetuximab Open
BACKGROUND: Cetuximab is a monoclonal antibody against epidermal growth factor receptor with activity against head and neck cancer and colorectal cancer. Anaphylaxis in response to cetuximab is a significant clinical problem in the Southea…
View article: Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC Open
Among patients with ALK+ but not ROS1+ mNSCLC, the presence of liver metastases at baseline and on-treatment was associated with worse survival. In the ALK+ population, the cumulative incidence of brain but not liver metastases is improvin…
View article: Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis Open
Patients with G719X alterations experienced longer TTD and OS with afatinib than osimertinib. In contrast, patients with L861Q alterations had longer TTD with osimertinib. In AM + CM pts, TTD and OS with osimertinib were longer than afatin…
View article: Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma
Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma Open
Background NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NUTM1 . BRD4::NUTM1 recruits p300 to acet…
View article: Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas
Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas Open
Introduction Pediatric sarcomas, including osteosarcoma (OS), Ewing sarcoma (EwS) and rhabdomyosarcoma (RMS) carry low somatic mutational burden and low MHC-I expression, posing a challenge for T cell therapies. Our previous study showed t…
View article: Bedside Utilization of Intestinal Pathology in Preterm Infants with Surgical Necrotizing Enterocolitis
Bedside Utilization of Intestinal Pathology in Preterm Infants with Surgical Necrotizing Enterocolitis Open
Necrotizing enterocolitis (NEC) is one of the most common conditions requiring emergency surgery in the neonatal intensive care unit and is associated with multiorgan dysfunction, multiple systemic morbidities, and mortality. The resected …
View article: Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer
Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer Open
Introduction Determining lines of therapy (LOT) using real‐world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non‐small cell lung cancer (mNSCLC)…
View article: Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis Open
Even in a contemporary era with prevalent osimertinib use, the baseline and longitudinal risk of BM development was high. The ongoing risk of developing BM, together with the associated survival detriment, argues for routine surveillance o…
View article: Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report Open
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3-targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome bu…
View article: Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer Open
Background We explored whether the disialoganglioside GD2 (GD2) is expressed in small cell lung cancer (SCLC) and non-SCLC (NSCLC) and can be targeted by GD2-specific chimeric antigen receptor (CAR) T cells. Methods GD2 expression was eval…
View article: Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer Open
Introduction Determining lines of therapy (LOT) using real-world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non-small cell lung cancer (mNSCLC)…
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Supplementary tables
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Supplementary figure legends
View article: Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
PFS and OS by AJCC 8
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Supplementary figure legends
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Supplementary tables
View article: Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Cytokines and Chemokines
View article: Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
PFS and OS by AJCC 8
View article: Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
B cell gating
View article: Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Cytokines and Chemokines
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Protocol
View article: Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
Protocol
View article: Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication Open
B cell gating